PMID- 37762991
OWN - NLM
STAT- Publisher
LR  - 20230930
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 18
DP  - 2023 Sep 19
TI  - Real-World Retrospective Study into the Effects of Oral Semaglutide (As a 
      Switchover or Add-On Therapy) in Type 2 Diabetes.
LID - 10.3390/jcm12186052 [doi]
LID - 6052
AB  - (1) Background: Oral semaglutide represents the first oral GLP-1 RA approved for 
      the treatment of type 2 diabetes mellitus (T2DM). This real-world retrospective 
      study aimed at evaluating its effectiveness and tolerability in the treatment of 
      patients with T2DM when patients switched from a glucose-lowering agent to it and 
      when it was added to the usual therapy. (2) Methods: Adult patients with T2DM 
      taking oral semaglutide and followed in the ASUGI Diabetes Center were identified 
      with the use of electronic medical records between October 2022 and May 2023. (3) 
      Results: A total of 129 patients were recruited. The median follow-up was 6 
      months. Be it as a switchover or as an add-on therapy, oral semaglutide 
      significantly reduced HbA1c and BMI. Switching from DPPIV inhibitors to oral 
      semaglutide was associated with a significant reduction in HbA1c and BMI, 
      switching from SGLT2 inhibitors was associated with a significant reduction in 
      HbA1c, and switching from sulphonylureas was associated with a significant 
      reduction in BMI. The median HbA1c change was associated with baseline HbA1c. SBP 
      significantly decreased in the add-on group. Oral semaglutide was well tolerated. 
      (4) Conclusions: This study shows that in the real-world setting, oral 
      semaglutide is effective and safe as a switchover or as an add-on therapy for the 
      treatment of T2DM.
FAU - Candido, Riccardo
AU  - Candido R
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
AD  - SC Patologie Diabetiche, ASUGI (Azienda Sanitaria Universitaria Giuliano 
      Isontina), 34128 Trieste, Italy.
FAU - Gaiotti, Sara
AU  - Gaiotti S
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Giudici, Fabiola
AU  - Giudici F
AUID- ORCID: 0000-0002-4160-3479
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Toffoli, Barbara
AU  - Toffoli B
AUID- ORCID: 0000-0002-6854-5782
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - De Luca, Federica
AU  - De Luca F
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Velardi, Valerio
AU  - Velardi V
AUID- ORCID: 0009-0001-4516-8427
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Petrucco, Alessandra
AU  - Petrucco A
AD  - SC Patologie Diabetiche, ASUGI (Azienda Sanitaria Universitaria Giuliano 
      Isontina), 34128 Trieste, Italy.
FAU - Gottardi, Chiara
AU  - Gottardi C
AD  - SC Patologie Diabetiche, ASUGI (Azienda Sanitaria Universitaria Giuliano 
      Isontina), 34128 Trieste, Italy.
FAU - Manca, Elena
AU  - Manca E
AD  - SC Patologie Diabetiche, ASUGI (Azienda Sanitaria Universitaria Giuliano 
      Isontina), 34128 Trieste, Italy.
FAU - Buda, Iris
AU  - Buda I
AD  - SC Patologie Diabetiche, ASUGI (Azienda Sanitaria Universitaria Giuliano 
      Isontina), 34128 Trieste, Italy.
FAU - Fabris, Bruno
AU  - Fabris B
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
AD  - SS Endocrinologia Medicina Clinica, ASUGI (Azienda Sanitaria Universitaria 
      Giuliano Isontina), 34128 Trieste, Italy.
FAU - Bernardi, Stella
AU  - Bernardi S
AUID- ORCID: 0000-0002-7429-3075
AD  - Department of Medical Surgical and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
AD  - SS Endocrinologia Medicina Clinica, ASUGI (Azienda Sanitaria Universitaria 
      Giuliano Isontina), 34128 Trieste, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230919
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10532177
OTO - NOTNLM
OT  - BMI
OT  - GLP-1 RA
OT  - HbA1c
OT  - oral semaglutide
OT  - real world
OT  - switch
OT  - type 2 diabetes mellitus
COIS- R.C. received grants, consultancy, and/or lecture fees from Abbott, AstraZeneca, 
      Bayer, Boehringer, Lilly, MSD, Menarini Diagnostics, Mundipharma, Novo Nordisk, 
      Roche Diabetes Care, and Sanofi. All the other authors declare no conflicts of 
      interest.
EDAT- 2023/09/28 06:42
MHDA- 2023/09/28 06:42
PMCR- 2023/09/19
CRDT- 2023/09/28 01:23
PHST- 2023/09/01 00:00 [received]
PHST- 2023/09/12 00:00 [revised]
PHST- 2023/09/14 00:00 [accepted]
PHST- 2023/09/28 06:42 [medline]
PHST- 2023/09/28 06:42 [pubmed]
PHST- 2023/09/28 01:23 [entrez]
PHST- 2023/09/19 00:00 [pmc-release]
AID - jcm12186052 [pii]
AID - jcm-12-06052 [pii]
AID - 10.3390/jcm12186052 [doi]
PST - epublish
SO  - J Clin Med. 2023 Sep 19;12(18):6052. doi: 10.3390/jcm12186052.